Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

Similar articles for PubMed (Select 22933738)

1.

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H.

Neurology. 2012 Sep 11;79(11):1130-5. doi: 10.1212/WNL.0b013e3182698c64. Epub 2012 Aug 29. Review.

2.

Perinatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs.

Lu E, Dahlgren L, Sadovnick A, Sayao A, Synnes A, Tremlett H.

Mult Scler. 2012 Apr;18(4):460-7. doi: 10.1177/1352458511422244. Epub 2011 Sep 13.

PMID:
21914689
3.

[Disease modifying drugs in multiple sclerosis and pregnancy].

Tur C, Tintoré M, Aguilera C.

Med Clin (Barc). 2012 Sep 22;139(7):316-8. doi: 10.1016/j.medcli.2012.04.021. Epub 2012 Jun 27. Spanish. No abstract available.

PMID:
22743277
4.

Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs.

Lu E, Zhu F, Zhao Y, van der Kop M, Synnes A, Dahlgren L, Sadovnick AD, Traboulsee A, Tremlett H.

CNS Drugs. 2014 May;28(5):475-82. doi: 10.1007/s40263-014-0154-6.

PMID:
24643915
5.

Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review.

Fragoso YD, Adoni T, Alves-Leon SV, Azambuja ND Jr, Barreira AA, Brooks JB, Carneiro DS, Carvalho MJ, Claudino R, Comini-Frota ER, Domingues RB, Finkelzstejn A, Gama PD, Giacomo MC, Gomes S, Goncalves MV, Grzesiuk AK, Kaimen-Maciel DR, Mendes MF, Morales NM, Morales RR, Muniz A, Papais-Alvarenga RM, Parolin MK, Ribeiro SB, Ruocco HH, Siquineli F, Tosta ED.

CNS Drugs. 2013 Nov;27(11):955-61. doi: 10.1007/s40263-013-0113-7.

PMID:
24114585
6.

Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.

Pecori C, Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Sturchio A, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, Mancardi GL, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP; MS Study Group of the Italian Neurological Society.

BMC Neurol. 2014 May 26;14:114. doi: 10.1186/1471-2377-14-114.

7.

Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review.

Charles JA, Tremlett H, Lu E, Guimond C, Sadovnick AD.

Neurology. 2013 Mar 12;80(11):1068-9. doi: 10.1212/01.wnl.0000428359.07207.f6. Review.

PMID:
23479468
8.

Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.

Giannini M, Portaccio E, Ghezzi A, Hakiki B, Pastò L, Razzolini L, Piscolla E, De Giglio L, Pozzilli C, Paolicelli D, Trojano M, Marrosu MG, Patti F, La Mantia L, Mancardi G, Solaro C, Totaro R, Tola MR, De Luca G, Lugaresi A, Moiola L, Martinelli V, Comi G, Amato MP.

BMC Neurol. 2012 Oct 22;12:124. doi: 10.1186/1471-2377-12-124.

9.

Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study.

Weber-Schoendorfer C, Schaefer C.

Mult Scler. 2009 Sep;15(9):1037-42. doi: 10.1177/1352458509106543.

PMID:
19692433
10.

Teriflunomide for multiple sclerosis.

He D, Xu Z, Dong S, Zhang H, Zhou H, Wang L, Zhang S.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2. Review.

PMID:
23235682
11.

Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.

Bonafede MM, Johnson BH, Wenten M, Watson C.

Clin Ther. 2013 Oct;35(10):1501-12. doi: 10.1016/j.clinthera.2013.07.330.

PMID:
24139422
12.

Natalizumab for relapsing remitting multiple sclerosis.

Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007621. doi: 10.1002/14651858.CD007621.pub2. Review.

PMID:
21975773
13.

The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.

Clerico M, Rivoiro C, Contessa G, Viglietti D, Durelli L.

Clin Neurol Neurosurg. 2008 Nov;110(9):878-85. doi: 10.1016/j.clineuro.2007.10.020. Epub 2008 Mar 4. Review.

PMID:
18164542
14.

Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review.

Balak DM, Hengstman GJ, Çakmak A, Thio HB.

Mult Scler. 2012 Dec;18(12):1705-17. doi: 10.1177/1352458512438239. Epub 2012 Feb 27. Review.

PMID:
22371220
15.

[How to manage medical treatment during pregnancy and childbirth].

Shimizu Y.

Nihon Rinsho. 2014 Nov;72(11):2053-60. Japanese.

PMID:
25518392
16.

Interferon beta, birth weight and pregnancy in multiple sclerosis.

Hellwig K, Agne H, Gold R.

J Neurol. 2009 May;256(5):830-1. doi: 10.1007/s00415-009-5014-9. Epub 2009 Feb 25. No abstract available.

PMID:
19240959
18.

Current recommendations for multiple sclerosis treatment in pregnancy and puerperium.

Ghezzi A, Annovazzi P, Portaccio E, Cesari E, Amato MP.

Expert Rev Clin Immunol. 2013 Jul;9(7):683-91; quiz 692. doi: 10.1586/1744666X.2013.811046. Review.

PMID:
23899239
19.

First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Johnston J, So TY.

Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000. Review.

PMID:
22642799
20.

Parenthood and immunomodulation in patients with multiple sclerosis.

Hellwig K, Haghikia A, Gold R.

J Neurol. 2010 Apr;257(4):580-3. doi: 10.1007/s00415-009-5376-z. Epub 2009 Nov 21.

PMID:
19936821
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk